When more is less and less is more: Is there an additional value of NT-proBNP in risk stratification in heart failure?

Abstract

Get full access to this article

View all access options for this article.

References

Ambrosy

Fonarow

Butler

et al.

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123–1133.

Mosterd

Cost

Hoes

et al.

The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001; 22: 1318–1327.

Levy

Kenchaiah

Larson

et al.

Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397–1402.

MacIntyre

Capewell

Stewart

et al.

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126–1131.

Hauptman

Swindle

Hussain

et al.

Physician attitudes toward end-stage heart failure: a national survey. Am J Med 2008; 121: 127–135.

Alba

Agoritsas

Jankowski

et al.

Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail 2013; 6: 881–889.

Ouwerkerk

Voors

Zwinderman

. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429–436.

Roberts

Ludman

Dworzynski

et al.

The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350: h910–h910.

Fonarow

Peacock

Phillips

et al.

Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 1943–1950.

10.

O’Brien

Squire

Demme

et al.

Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5: 499–506.

11.

Logeart

Thabut

Jourdain

et al.

Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641.

12.

Masson

Latini

Anand

et al.

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008; 52: 997–1003.

13.

Berger

Huelsman

Strecker

et al.

B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392–2397.

14.

Neuhold

Huelsmann

Strunk

et al.

Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008; 52: 266–272.

15.

Latini

Masson

Wong

et al.

Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119: 70.e23–70.e30.

16.

Arzilli C, Aimo A, Vergaro G, et al. N-terminal fraction of pro-B-type natriuretic peptide vs. clinical risk scores for prognostic stratification in chronic systolic heart failure. Eur J Prev Cardiol 2018; 25: 889–895.

17.

Senni

Parrella

De Maria

et al.

Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. Int J Cardiol 2013; 163: 206–211.

18.

Levy

Mozaffarian

Linker

et al.

The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424–1433.

19.

Hlatky

Greenland

Arnett

et al.

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408–2416.

20.

Pencina

D’Agostino

Sr D’Agostino

Jr et al.

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172. discussion 207–212.

21.

Ponikowski

Voors

Anker

et al.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.

22.

Melander

Newton-Cheh

Almgren

et al.

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302: 49–57.

23.

Steinberg

Zhao

Heidenreich

et al.

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65–75.

24.

Chioncel

Lainscak

Seferovic

et al.

Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574–1585.

25.

O’Connor

Hasselblad

Mehta

et al.

Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010; 55: 872–878.

26.

Scrutinio

Ammirati

Guida

et al.

Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. Int J Cardiol 2013; 168: 2120–2126.

27.

Salah

Kok

Eurlings

et al.

A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart 2014; 100: 115–125.

28.

Barlera

Tavazzi

Franzosi

et al.

Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail 2013; 6: 31–39.

29.

Dunlay

Gerber

Weston

et al.

Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009; 2: 393–400.

30.

Lassus

Gayat

Mueller

et al.

Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013; 168: 2186–2194.

31.

Jackson

Haig

Welsh

et al.

The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail 2016; 18: 1491–1498.

32.

Januzzi

Jr Rehman

Mohammed

et al.

Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58: 1881–1889.

33.

Berger

Moertl

Peter

et al.

N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55: 645–653.

34.

Lainchbury

Troughton

Strangman

et al.

N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55: 53–60.

35.

Eurlings

van Pol

Kok

et al.

Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010; 56: 2090–2100.

36.

Pfisterer

Buser

Rickli

et al.

BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301: 383–392.

37.

Felker

Anstrom

Adams

et al.

Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017; 318: 713–720.